Medtronic stock has delivered a decline of about 24% over the past five years, yet current valuation checks send a mixed message as the Discounted Cash Flow (DCF) intrinsic value points to roughly fair pricing while earnings based multiples lean more supportive.

• Over five years, Medtronic has fallen 23.7%, which puts more focus on whether today’s price fairly reflects its long term earnings power.
• Recent progress in higher end monitoring and renal denervation therapies can support long run cash flows. However, execution risk around new product rollouts and reimbursement remains a key swing factor for valuation.
• On Simply Wall St’s checks, Medtronic screens as reasonably priced on some measures but less so on others. The stock passes 4 of 6 valuation tests, a mixed picture rather than a clear bargain or clear premium, and you can see the detail at 4 of 6.

The issue now is whether Medtronic’s current share price already reflects its cash flow potential or still leaves room for upside based on intrinsic value and market multiples.

Is Medtronic Fairly Priced on Cash Flow?

The Discounted Cash Flow (DCF) model values Medtronic by estimating the cash it could return to shareholders over time and discounting that back to today. For Medtronic, the latest twelve month free cash flow sits at about $5.4b, and the model assumes these cash flows keep growing rather than shrinking. On that basis, the DCF points to an estimated intrinsic value of about $86 per share.

With Medtronic trading close to that level, the implied discount of roughly 3.7% suggests the stock is only slightly below the DCF estimate and therefore screens as roughly fairly valued on cash flows. Because the expanded partnership to distribute the Argos Cardiac Output Monitor reflects ongoing investment in monitoring technologies, the market may already be giving some credit for future cash flows from these kinds of products.

Overall, Medtronic appears roughly fairly valued on a cash flow basis, with the current price sitting close to the DCF intrinsic value.

Medtronic is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Does Medtronic Look Undervalued on Earnings?

P/E makes sense for Medtronic because earnings are a key focus for investors in established medical equipment businesses. Medtronic currently trades on a P/E of about 22.2x, which is below both the Medical Equipment industry average of 26.5x and a peer group average near 33.4x. Based on Simply Wall St’s estimates, a more tailored fair P/E that reflects Medtronic’s scale, margins and risk profile is closer to 29.3x.

That fair multiple is noticeably higher than where Medtronic stock trades today, so the shares appear to trade at a discount on earnings even after considering sector norms and similar companies. This indicates that the market price may not fully reflect the earnings that Medtronic is currently generating, including from product work in areas such as monitoring and renal denervation therapies.

On the P/E multiple, Medtronic stock appears undervalued relative to what its earnings profile would typically justify.

The Medtronic Narrative: What Would Justify Today's Price?

Simply Wall St Narratives help connect Medtronic's mixed valuation signals to the expectations that would need to play out on growth, margins and earnings for the stock to be worth significantly more or less than it is today, and they sit on the company’s Community page. Rather than relying on a single multiple or DCF output, each narrative lays out the assumptions that underpin its view of fair value so you can compare them with Medtronic's reported results over time.

Community views on where Medtronic should trade sit quite far apart, with one side focusing on product momentum and the other stressing execution risk and tempered assumptions.

Bull case: 15% undervalued

"Strengthening the innovation pipeline (e.g., Sphere-360, new carotid and thrombectomy devices, next-gen Ardian) combined with an enhanced governance/capital allocation structure and intensified R&D investment is positioned to drive higher long-term earnings growth through both new product launches and share gains in multi-billion-dollar addressable markets..."

Bear case: 7% overvalued

"This narrative explores a more pessimistic perspective on Medtronic compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts..."

Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!

The Bottom Line

Medtronic looks roughly in line with its Discounted Cash Flow (DCF) intrinsic value, while its P/E suggests the stock is undervalued compared with sector peers and a tailored fair multiple. That split reflects different emphases, cash flow timing and capital intensity on one side, and earnings expectations and sentiment on the other. The broader checks produce a mixed overall read. From here, the key question is whether Medtronic can execute consistently on its product pipeline and reimbursement hurdles so that the earnings profile the multiples point to is sustained, rather than the current discount proving to be a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.